Unibest

Pharmaceutical intermediates

ZURANOLONE Intermediates

6 pharmaceutical intermediates for ZURANOLONE. Indication: Postpartum Depression.

提交项目All intermediates

About ZURANOLONE

Originator
Sage Therapeutics Inc.; Shionogi Pharmaceutical Co., Ltd.
Indication
Postpartum Depression
Approved Date
10/31/2023
NCE Patent
10/31/2028
DS/DP
04/17/2034

Available intermediates

6 intermediates currently listed for ZURANOLONE. Request specifications, documentation or a quotation for any item below.

ZURANOLONE intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(5R,8R,9R,10S,13S,14S)-13-Methyldodecahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,4H)-dione5696-51-5//
(3R,5R,8R,9R,10S,13S,14S)-3-hydroxy-3,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one1632051-92-3//
19-Norpregn-17(20)-en-3-ol, 3-methyl-, (3α,5β)-1430063-91-4//
(3R,5R,8R,9R,10S,13S,14S,17S)-17-(1-hydroxyethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-ol1430063-92-5//
2-bromo-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone1430063-93-6//
1H-pyrazole-4-carbonitrile31108-57-3//

Other programs under Z

ZavegepantZelicapavirZipalertinibZiprasidone Hydrochloride

Building toward ZURANOLONE?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →